OCT 30, 2014 6:00 AM PDT

A platform for combining the results of WES and RNA-seq analysis

Speaker
  • Director, Clinical Analytics and Workflow Products, CLC Bio, a Qiagen company
    Biography
      Naomi is greatly experienced within the field of bioinformatics from where she has gained a tremendous amount of customer, product, and sequencing experience through the past 15 years. Naomis pre-business experience is loaded with nucleic acids and oncology at Bristol-Myers Squibb and The Wistar Institute, along with an MBA from La Salle University. Naomi has also been working 10 years as a Product Manager and nearly five years as an NGS Key Account Manager before heading the product management of Clinical Analytics and Workflow products at QIAGEN.

    Abstract

    Cancer research is being revolutionized by targeted gene panels, whole exome sequencing (WES), whole genome sequencing (WGS), and transcriptome sequencing (RNA-Seq). Many analyses, such as comparison of tumor and normal cells, include comparison of variant calls. In this webinar, we will illustrate the benefits of leveraging read mappings in the comparison of WES and RNA-seq data using CLC Cancer Research Workbench. The CLC platform provides a number of tools, together building up a workflow, for analyzing WES and RNA-seq reads and for comparing the results. From this webinar you will learn how to analyse and compare variants from two patients using built-in workflows in CLC Cancer Research Workbench; Analysis steps include filtering results for tumor-specific variants, identifying variants from both WES and RNA-seq data, searching RNA-seq read mappings for variants previously called from exome data, and recovering previously detected variants in the WES data directly from the RNA-seq read mappings.


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    SEP 03, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 03, 2020 9:00 AM PDT
    DATE: September 3, 2020 TIME: 09:00am PT, 12:00pm ET xxx Learning Objectives: xxx Webinars will be available for unlimited on-demand viewing after live event. LabRoots is approved as a provi...
    DEC 03, 2020 4:30 PM PST
    C.E. CREDITS
    DEC 03, 2020 4:30 PM PST
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    JUN 17, 2020 1:30 PM PDT
    C.E. CREDITS
    JUN 17, 2020 1:30 PM PDT
    Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
    Loading Comments...
    Show Resources
    Attendees
    • See more